The only treatment I’m aware of is Pfizer’s Vyndamax which prevents future amyloid build up. Currently no treatment to reverse the disease, or remove existing deposits.

Alnylam Presents 18-Month Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy

As previously announced, the U.S. FDA has set an action date of October 8, 2023 under the Prescription Drug User Fee Act (PDUFA) and noted that they are planning to convene a meeting of the Cardiovascular and Renal Drugs Advisory Committee to discuss the application. Patisiran is the established name for ONPATTRO®, which is approved by the U.S. FDA for the treatment of the polyneuropathy of hereditary ATTR amyloidosis in adults.

https://www.businesswire.com/news/home/20230520...